Keywords: teva, rasagiline, promising, early, parkinson, results, 404-patient

Teva's rasagiline promising in early Parkinson's?

Article | 20 January 2003

Print This

The results of a 404-patient Phase III study of Teva Pharmaceuticals'monoamine oxidase B inhibitor, rasagiline mesylate, have pointed to a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in